RhumbLine Advisers’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-98,289
| Closed | -$2.35M | – | 3205 |
|
|
2021
Q1 | $2.35M | Sell |
98,289
-12,009
| -11% | -$223K | ﹤0.01% | 1840 |
|
|
2020
Q4 | $1.61M | Buy |
110,298
+1,680
| +2% | +$22.3K | ﹤0.01% | 1947 |
|
|
2020
Q3 | $1.54M | Sell |
108,618
-12,015
| -10% | -$184K | ﹤0.01% | 1817 |
|
|
2020
Q2 | $1.77M | Buy |
120,633
+26,862
| +29% | +$273K | ﹤0.01% | 1797 |
|
|
2020
Q1 | $386K | Sell |
93,771
-500
| -0.5% | -$2.34K | ﹤0.01% | 2281 |
|
|
2019
Q4 | $453K | Buy |
94,271
+1,372
| +1% | +$7.57K | ﹤0.01% | 2410 |
|
|
2019
Q3 | $563K | Sell |
92,899
-2,950
| -3% | -$18.4K | ﹤0.01% | 2269 |
|
|
2019
Q2 | $622K | Buy |
95,849
+5,807
| +6% | +$40.9K | ﹤0.01% | 2269 |
|
|
2019
Q1 | $638K | Sell |
90,042
-2,000
| -2% | -$13.2K | ﹤0.01% | 2222 |
|
|
2018
Q4 | $447K | Buy |
92,042
+46,236
| +101% | +$241K | ﹤0.01% | 2348 |
|
|
2018
Q3 | $337K | Sell |
45,806
-3,280
| -7% | -$24.1K | ﹤0.01% | 2463 |
|
|
2018
Q2 | $313K | Buy |
49,086
+5,309
| +12% | +$35.1K | ﹤0.01% | 2508 |
|
|
2018
Q1 | $238K | Sell |
43,777
-550
| -1% | -$2.73K | ﹤0.01% | 2543 |
|
|
2017
Q4 | $185K | Sell |
44,327
-4,893
| -10% | -$29.4K | ﹤0.01% | 2653 |
|
|
2017
Q3 | $474K | Buy |
49,220
+775
| +2% | +$8.05K | ﹤0.01% | 2335 |
|
|
2017
Q2 | $573K | Buy |
48,445
+408
| +0.8% | +$5.22K | ﹤0.01% | 2230 |
|
|
2017
Q1 | $616K | Buy |
48,037
+2,321
| +5% | +$27.9K | ﹤0.01% | 2160 |
|
|
2016
Q4 | $560K | Sell |
45,716
-1,482
| -3% | -$17.6K | ﹤0.01% | 2165 |
|
|
2016
Q3 | $557K | Buy |
47,198
+900
| +2% | +$8.69K | ﹤0.01% | 2132 |
|
|
2016
Q2 | $403K | Buy |
46,298
+4,849
| +12% | +$33.2K | ﹤0.01% | 2345 |
|
|
2016
Q1 | $218K | Buy |
41,449
+650
| +2% | +$3.62K | ﹤0.01% | 2699 |
|
|
2015
Q4 | $317K | Buy |
40,799
+3,490
| +9% | +$26.8K | ﹤0.01% | 2544 |
|
|
2015
Q3 | $294K | Buy |
37,309
+1,429
| +4% | +$13.2K | ﹤0.01% | 2557 |
|
|
2015
Q2 | $325K | Sell |
35,880
-3,135
| -8% | -$31.6K | ﹤0.01% | 2606 |
|
|
2015
Q1 | $506K | Buy |
39,015
+6,725
| +21% | +$87.9K | ﹤0.01% | 2294 |
|
|
2014
Q4 | $439K | Buy |
32,290
+1,000
| +3% | +$11.2K | ﹤0.01% | 2346 |
|
|
2014
Q3 | $281K | Hold |
31,290
| – | – | ﹤0.01% | 2562 |
|
|
2014
Q2 | $423K | Buy |
31,290
+5,598
| +22% | +$58.4K | ﹤0.01% | 2378 |
|
|
2014
Q1 | $255K | Sell |
25,692
-1,420
| -5% | -$17.6K | ﹤0.01% | 2635 |
|
|
2013
Q4 | $361K | Buy |
27,112
+1,300
| +5% | +$15.8K | ﹤0.01% | 2461 |
|
|
2013
Q3 | $314K | Buy |
25,812
+282
| +1% | +$3.02K | ﹤0.01% | 2499 |
|
|
2013
Q2 | $264K | Buy |
+25,530
| New | +$352K | ﹤0.01% | 2759 |
|
RhumbLine Advisers's GNMK Position: Q2 2021 in Review
RhumbLine Advisers sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 98,289 shares — an estimated $2.35M sold.
RhumbLine Advisers first reported a position in GNMK in Q2 2013 and held it in 32 quarters. The position peaked at $2.35M in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- RhumbLine Advisers reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- RhumbLine Advisers sold 98,289 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $2.35M.
- RhumbLine Advisers first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 32 quarters.
- RhumbLine Advisers's GenMark Diagnostics, Inc position peaked at $2.35M in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.